FDA flags Evolus' Jeuveau Instagram reel for blurring the line between Rx injectable and beauty bag
The FDA has flagged an Instagram reel for Evolus' frown-line injectable, Jeuveau, accusing the company of misleading consumers. The regulator criticized the reel for overstating the drug's efficacy and speed, and for marketing a prescription neurotoxin as casually as a beauty product, thereby minimizing risks. This action is part of a sustained crackdown by the FDA on deceptive drug advertising.
Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug - Evolus (NASDAQ:EOLS)
The U.S. FDA's Office of Prescription Drug Promotion issued a warning letter to Evolus Inc. regarding misleading Instagram promotions for its frown line treatment, Jeuveau. The agency found that the social media content exaggerated efficacy, downplayed safety risks, and improperly compared the prescription drug to cosmetic items. Evolus has been given 15 working days to respond with a plan to address the violative promotional materials.
FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action
The FDA has flagged an Instagram promotion for Evolus' (EOLS) wrinkle treatment, Jeuveau, as "false or misleading," causing the company's shares to fall. The agency objected to claims about "gone" frown lines, "complete results," and rapid action, stating that supporting studies primarily measured efficacy at Day 30, not Day 2. Evolus has been given 15 working days to respond and outline corrective actions for its promotional materials.
Evolus (EOLS) Shares Fall After FDA Warning on Jeuveau Instagram Post
Evolus (EOLS) shares dropped after the FDA issued a warning regarding a misleading Instagram post for its product, Jeuveau, requiring a corrective action plan. The company's Price-to-Sales ratio is low compared to its historical median, reflecting market skepticism, and traditional P/E metrics are not applicable due to ongoing losses. While institutional gurus show some confidence, insiders have been net sellers, presenting a complex and speculative investment picture for Evolus.
Evolus Inc (0K16) Q3 2024 Earnings Report - Results, Call & Slides
Evolus Inc (0K16) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -$0.16 against a consensus of -$0.12, and actual revenue of $61.09M compared to an expected $63.17M, though revenue still grew 22.12% year-over-year. The earnings call took place on November 6, 2024, and the next earnings report is estimated for November 10, 2026.
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
Evolus, Inc. has launched "Wings by Evolus," a new charitable platform to mobilize its community of aesthetic practices, providers, and patients for important causes. The first initiative will support Look Good Feel Better® during Breast Cancer Awareness Month in October 2026, with Evolus donating $1 for every patient check-in at participating practices. This platform aims to leverage the collective strength of the Evolus community to create a positive impact, starting with an organization that helps cancer patients manage appearance-related treatment effects and restore confidence.
At participating practices, each patient check-in will send $1 to cancer support.
Evolus (EOLS) has launched "Wings by Evolus," a new charitable platform designed to unite aesthetic practices, providers, and patients to support various causes. The first initiative, in honor of Breast Cancer Awareness Month, will support Look Good Feel Better, a global cancer support program. Throughout October, Evolus will donate $1 to the Look Good Feel Better Foundation for every Evolus Rewards patient check-in at participating practices.
How (EOLS) Movements Inform Risk Allocation Models
The article discusses how Evolus Inc. (EOLS) stock movements inform risk allocation models, highlighting divergent sentiment across different time horizons, suggesting choppy conditions. It presents three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for various risk profiles, along with multi-timeframe signal analysis. The analysis indicates a significant 79.5:1 risk-reward short setup, targeting an 18.4% downside with minimal risk.
Discover Evolus And Two Other Growth Companies With Strong Insider Backing
This article identifies three growth companies—Evolus (EOLS), Forbright (FRBT), and Ryan Specialty Holdings (RYAN)—with significant insider ownership that may signal confidence in their future success. Evolus, a performance beauty company, is forecasted for 69.8% annual earnings growth and recently raised its 2026 guidance. Forbright, a bank holding company, is expected to see 37.6% annual earnings growth and is trading at a discount to its estimated fair value. Ryan Specialty Holdings, an insurance service provider, projects 44.8% annual earnings growth, though its revenue growth is slower than the market average.
Discover Evolus And Two Other Growth Companies With Strong Insider Backing
This article highlights Evolus (EOLS), Forbright (FRBT), and Ryan Specialty Holdings (RYAN) as growth companies with strong insider backing and promising financial outlooks. It discusses their revenue and earnings growth forecasts, insider ownership percentages, and recent strategic developments, emphasizing that high insider ownership often signals confidence in a company's future success. The piece also provides a broader context of the US market's performance and identifies other growth companies with significant insider ownership.
EOLS 8-K Filings - Evolus, Inc. SEC 8-K
This article provides a compilation of Evolus, Inc. (EOLS) 8-K filings with the SEC over the last 24 months, detailing significant corporate events. These filings include financial results, guidance updates, licensing agreements for new products, and resolutions from annual stockholder meetings. The reports highlight the company's strategic growth initiatives and financial performance, such as revenue increases and adjusted EBITDA.
Evolus Insider MOATAZEDI DAVID Sells 105,108 Shares at $9.04 Each (NASDAQ: EOLS)
Evolus insider MOATAZEDI DAVID sold 105,108 shares of the company's stock at a price of $9.04 per share. This transaction occurred on September 2, 2026, and leaves MOATAZEDI DAVID with 499,592 shares remaining in Evolus, Inc. The sale is noted with a "See Remarks" designation.
Evolus president & CEO David Moatazedi sells $950,018 in shares
David Moatazedi, President and CEO of Evolus Inc. (NASDAQ:EOLS), sold 105,108 shares of the company's common stock for a total of $950,018 on September 2, 2026. This sale occurred while Evolus stock was trading near its 52-week high, following a 66% surge in the past six months, though it remains undervalued according to InvestingPro analysis. Moatazedi now directly holds 499,592 shares, and the company recently reported strong Q2 revenue surpassing expectations, despite a wider-than-expected loss per share.
Insider at Evolus (NASDAQ: EOLS) moves to sell nearly $1M in stock
An insider at Evolus, Inc. (EOLS), David Moatazedi, has filed a Rule 144 notice to sell up to 105,108 common shares, valued at approximately $950,018.66. The shares, consisting of performance and restricted stock awarded in 2025 and 2026, are intended to be sold through Morgan Stanley Smith Barney LLC. This filing signals a proposed significant insider transaction for the company.
Evolus (EOLS) adds Soleus group as new 5.3% shareholder
A group of affiliated Soleus entities and Guy Levy have reported beneficial ownership of 3,480,000 shares of Evolus (EOLS) common stock, representing a 5.3% stake in the company. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The 5.3% ownership is based on 66,050,440 shares of Evolus common stock outstanding as of July 31, 2026.
(EOLS) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily discusses Evolus Inc. (NASDAQ: EOLS) and its movement as an input in quant signal sets. It highlights strong near and mid-term sentiment, potential upside due to a lack of resistance levels, and provides institutional trading strategies including position trading, momentum breakout, and risk hedging. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Evolus Stock Price Forecast. Should You Buy EOLS?
StockInvest.us has rated Evolus Inc. (EOLS) as a Buy Candidate with a technical score of 4.63, unchanged from its previous evaluation. The stock has shown positive short and long-term moving averages, indicating a positive forecast, and has risen 11.95% since a buy signal on August 12, 2026. Despite some negative signals like falling volume on rising prices and a MACD sell signal, the stock is seen as a buying opportunity due to its strong short-term trend and attractive risk-reward profile.
August 2026's Leading Growth Companies With Insider Confidence
The article highlights top growth companies in the United States with high insider ownership, indicating strong internal confidence. It details companies like Webull, Evolus, and Victoria's Secret, providing an overview of their operations, growth forecasts, and recent developments. The piece suggests that high insider ownership, coupled with robust earnings growth, makes these companies attractive investment prospects.
Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS
Renaissance Technologies LLC significantly reduced its stake in Evolus, Inc. (NASDAQ:EOLS) by 57.6% in the first quarter, selling 460,875 shares and retaining 339,025 shares valued at $1.39 million. Despite this, institutional investors collectively own about 90.69% of Evolus, and several other funds have recently increased or initiated positions. Analysts maintain a "Moderate Buy" consensus rating for Evolus with an average price target of $14.50, significantly higher than its recent share price of $8.12.
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS
Assenagon Asset Management S.A. significantly increased its stake in Evolus, Inc. (NASDAQ:EOLS) by 51.8% in the second quarter, now holding 908,180 shares valued at approximately $6.3 million. This move is part of a trend among institutional investors, who collectively own 90.69% of Evolus stock. The company maintains a "Moderate Buy" consensus rating from analysts, with shares trading above their 50-day and 200-day moving averages.
Trading Systems Reacting to (EOLS) Volatility
This article analyzes Evolus Inc. (NASDAQ: EOLS) using AI models to generate trading strategies. It highlights strong near and mid-term sentiment but a weak long-term outlook, identifying compelling upside potential as no resistance levels remain above the current price. The analysis provides specific entry, target, and stop-loss points for position, momentum breakout, and risk hedging strategies, alongside multi-timeframe signal analysis.
Evolus Inc (EOLS) Stock News Today
This page provides an overview of Evolus Inc (EOLS) stock news, earnings, analyst ratings, and key developments. It notes the current stock price, market cap, and indicates that more news will be coming soon. The page serves as a hub for investors to track information related to EOLS.
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded Evolus (NASDAQ:EOLS) from a "hold" to a "buy" rating, contributing to a "Moderate Buy" consensus among analysts with an average price target of $14.50. Shares of Evolus opened at $7.59, a 2.4% increase, and are nearing their 12-month high. Institutional ownership of Evolus is substantial at 90.69%, indicating strong investor confidence.
Evolus, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EOLS) 2026-08-06
This article announces that Evolus, Inc. (EOLS) published its Q2 2026 earnings call presentation on August 6, 2026. The company reported Q2 EPS of -$0.02, beating estimates by $0.02, and revenue of $84.08 million, a 21.18% year-over-year increase, beating estimates by $2.54 million. The content highlights the availability of the slide deck from their earnings call.
Evolus Inc. Earnings Call Signals Confident Growth
Evolus, Inc. reported strong Q2 earnings with double-digit revenue growth and a third consecutive quarter of positive adjusted EBITDA, driven by its toxin franchise and growing international presence. Despite increased operating expenses and tariff uncertainty, the company raised its 2026 revenue guidance and reaffirmed long-term targets, signaling a confident outlook for profitable expansion. The company emphasized portfolio diversification and strategic investments, including a new skin quality licensing deal, as key drivers for future growth.
Evolus Inc (EOLS) News, Articles, Events & Latest Updates
This article provides a compilation of recent news, articles, and updates concerning Evolus Inc (EOLS). Key highlights include Evolus reporting strong Q2 2026 financial results with positive adjusted EBITDA, expanding partnerships, and announcing future earnings report dates. The company also reported inducement grants of restricted stock units and a significant partnership with IBSA to develop and commercialize Profhilo in the US.
Evolus, Inc. Q2 2026: Revenue $84.08M, EPS ($0.12) — 10-Q Summary
Evolus, Inc. reported its Q2 2026 financial results, with revenue increasing to $84.08 million from $69.39 million in the prior year quarter, marking a 21.2% year-over-year growth. The company also narrowed its net loss, reporting a diluted EPS of ($0.12) compared to ($0.27) a year earlier. Key business highlights included strong sales of Jeuveau®, the European launch of Evolysse®, and strategic expansion of distribution rights for its products.
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Evolus, Inc. (EOLS) reported break-even earnings per share for Q2, outperforming the Zacks Consensus Estimate of a $0.01 loss and significantly improving from a $0.24 loss a year ago. The company also surpassed revenue estimates, posting $84.08 million for the quarter. Despite current market underperformance, its Zacks Rank #3 (Hold) suggests it will perform in line with the market.
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Evolus, Inc. (EOLS) reported break-even quarterly earnings per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $0.01 loss and significantly improving from a $0.24 loss a year ago. The company also exceeded revenue expectations, posting $84.08 million against an estimated $82.02 million. Despite outperforming earnings estimates three out of the last four quarters and revenue estimates consistently, Evolus's stock has lost 8% year-to-date, contrasting with the S&P 500's 13% gain.
Evolus Q2 2026 slides: profitability streak continues, guidance raised
Evolus Inc. reported strong Q2 2026 results, with revenue up 21% year-over-year to $84.1 million, marking its third consecutive quarter of positive adjusted EBITDA. The company raised its full-year 2026 revenue guidance to $330-$337 million and reaffirmed its long-term target of $450-$500 million by 2028, driven by its expanding portfolio of aesthetic injectables and a digital-first customer engagement strategy. Despite a wider-than-expected adjusted loss per share, investors reacted positively to the revenue beat and improved outlook, as Evolus transitions from a single-product business to a diversified aesthetics platform.
Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses
Evolus (EOLS) reported strong Q2 2026 earnings with revenue reaching $84.1 million, a 21.2% increase year-over-year, and slightly exceeding estimates. The company also narrowed its net and operating losses, reporting a net loss of $8.1 million and diluted EPS of -$0.12. Insider trading activity showed four sales and no purchases in the last six months, while hedge funds demonstrated mixed sentiment, with some significantly increasing and others decreasing their positions.
Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses
Evolus (EOLS) reported strong Q2 2026 earnings, with revenue reaching $84.1 million, a 21.2% increase year-over-year, and slightly exceeding analyst estimates. The company also improved its financial performance by narrowing its operating and net losses. Insider trading activity showed sales by executives, while institutional investors had mixed movements in their holdings.
Evolus (NASDAQ: EOLS) lifts 2026 guidance after Q2 revenue hits $84.1 million
Evolus (NASDAQ: EOLS) reported strong Q2 2026 financial results with net revenue of $84.1 million, a 21% increase year-over-year, and positive adjusted EBITDA of $4.7 million. This marks the third consecutive quarter of positive adjusted EBITDA for the company. Consequently, Evolus has raised its full-year 2026 net revenue guidance to between $330 million and $337 million and its adjusted gross profit margin guidance to 67.0% to 67.5%, while reaffirming its 2028 long-term financial outlook.
Perceptive Advisors LLC Acquires New Stake in Evolus, Inc. $EOLS
Perceptive Advisors LLC has acquired a new stake in Evolus, Inc. (NASDAQ:EOLS), purchasing 1,286,862 shares valued at approximately $5.3 million, giving them a 1.95% ownership. Evolus reported revenue slightly above estimates but an adjusted loss that missed expectations. Despite a consensus "Moderate Buy" rating from analysts with a target price of $16.00, the stock is currently trading at $5.84.
Evolus Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Evolus, Inc. (NASDAQ: EOLS) and reminds investors of the December 15, 2020 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Evolus made false and misleading statements regarding the origin and manufacturing process of its Jeuveau™ product, which were purportedly misappropriated from Medytox. The firm encourages investors who suffered losses exceeding $100,000 to contact them to discuss their legal options.
Evolus, Inc. (NASDAQ: EOLS) extends Estyme deal to $500M markets
Evolus, Inc. has expanded its licensing agreement with Symatese Aesthetics to include exclusive commercialization rights for the Estyme® injectable hyaluronic acid gels in Canada, Australia, and New Zealand. This expansion, costing Evolus an upfront payment of €920,000 and potential regulatory milestone payments of up to €1.38 million, aims to commercialize the product by 2028. The company targets a combined annual market of approximately $500 million for neurotoxins and dermal fillers in these regions, expecting the deal to enhance international gross margins and leverage its existing commercial infrastructure.
Evolus expands hyaluronic acid gel rights to three markets
Evolus Inc. has expanded its licensing and distribution agreement with Symatese to gain exclusive rights for commercializing Estyme injectable hyaluronic acid gels in Canada, Australia, and New Zealand. This move adds three new markets to Evolus's hyaluronic acid gel portfolio, with commercialization expected by 2028, subject to regulatory approvals. The company anticipates this expansion will strengthen its competitive position and be accretive to its international gross margins.
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
Evolus, Inc. has expanded its partnership with Symatese to gain exclusive rights to commercialize the Estyme® collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zealand. This expansion will complement Evolus' existing neurotoxin offerings (Jeuveau® and Nuceiva®) in these markets, creating a consistent multi-product commercial platform globally. The agreement is expected to be accretive to Evolus' international gross margins and leverage its existing commercial infrastructure, with commercialization anticipated in 2028 pending regulatory approvals.
Evolus Number of Employees 2026 | Employee Count & Headcount Data
Evolus, Inc. (EOLS) had approximately 348 employees worldwide as of March 2026, marking a 50.4% growth since 2023 but a 4.0% decline year-over-year in 2026. The company is actively hiring, with 53 job postings in 2026, and its workforce is predominantly located in the United States. The average salary is $137,590, and overall employee sentiment is neutral but declining.
Evolus Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance
This article provides a detailed profile of Evolus, Inc. (EOLS), a performance beauty company specializing in cash-pay aesthetic medical products. It outlines the company's key products, Jeuveau and Evolysse, and includes essential corporate information such as its CEO, IPO date, employee count, and contact details. The article also lists company executives with their shareholdings and provides data on institutional ownership of Evolus Inc.
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis
The financial score for Evolus Inc (EOLS) is 8.00, placing it 82nd out of 155 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company reported a 6.74% year-over-year increase in its latest quarterly revenue to $73.14M and a 43.50% increase in net profit. While some financial data for specific metrics like cash equivalents, total assets, and free cash flow were not disclosed, its operational efficiency and growth potential scores are high.
Evolus Shareholder Alert
Faruqi & Faruqi, LLP, a securities law firm, is investigating potential claims against Evolus, Inc. following a federal securities class action lawsuit. The lawsuit alleges that Evolus made false statements regarding the origin of its Jeuveau™ product and misappropriated trade secrets from Medytox. This led to a significant stock drop after the U.S. International Trade Commission recommended banning the import and sale of Jeuveau™.
How Evolus Inc. (EOLS) Affects Rotational Strategy Timing
This article analyzes Evolus Inc. (EOLS) utilizing AI models to provide insights for a rotational strategy. It highlights a near-term strong sentiment challenging persistent mid and long-term weakness and identifies a significant risk-reward setup. The analysis offers three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various horizons.
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Evolus Inc (EOLS), detailing its price movement, support and resistance levels, and insights from various technical indicators and moving averages. The stock currently has a price momentum score of 4.73 and is trading between a resistance of $7.16 and support of $5.37. While some indicators suggest a "Sell" or "Neutral" signal, moving averages largely indicate a "Buy" signal.
Evolus Inc (EOLS) Institutional Confidence
The article provides an overview of Evolus Inc's institutional confidence, detailing its current score, industry ranking, and institutional shareholding proportion, which has decreased by 14.84% quarter-over-quarter. It lists key institutional shareholders and their recent activity. The institutional shareholding score for EOLS is 7.00, placing it 50th out of 155 in the Pharmaceuticals industry.
Evolus Market Sentiment
This article analyzes market sentiment for Evolus (EOLS) through key signals like analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with an average price target significantly above the current stock price, despite some recent downgrades and maintained ratings. The article also touches on recent insider buying activity and upcoming earnings information for Evolus.
Evolus Inc (EOLS) Cash Flow
This article provides a detailed historical cash flow statement for Evolus Inc (EOLS), covering annual and quarterly data across various financial metrics like operating, investing, and financing cash flows. It includes period-over-period changes and absolute values for numerous line items, allowing for an in-depth analysis of the company's financial liquidity and health. The data spans from FY2016Q3 to FY2026Q1, highlighting trends in net income, capital expenditures, and changes in working capital.
Evolus Inc (EOLS) Income Statement
This article provides the quarterly and annual income statement for Evolus Inc (EOLS), detailing key financial metrics such as total revenue, cost of revenue, operating expenses, operating profit, and net income. It allows users to gain insights into the company's financial performance and operational efficiency over various periods. The page also includes FAQs explaining how to interpret the income statement and defining important financial terms like YOY (year over year) and EPS (earnings per share).
Evolus Inc (EOLS) Balance Sheet
This article provides the quarterly and annual balance sheets for Evolus Inc (EOLS), allowing users to evaluate the company's financial health, fundamentals, and key financial ratios. It details assets, liabilities, and shareholder equity over various fiscal quarters, and includes a FAQ section defining key financial terms and recent figures for EOLS.
Evolus Inc (EOLS) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides information regarding Evolus Inc (EOLS) stock, focusing on its dividend history. It states that Evolus Inc has not distributed any dividends over the past five years. The page displays current stock metrics such as its closing price, market capitalization, and P/E TTM.
